Last updated: August 30, 2026
Sodium sulfate, potassium sulfate and magnesium sulfate oral solution is a mature prescription bowel-preparation product best known under the brand SUPREP Bowel Prep Kit. The product is marketed for colonoscopy preparation and competes in a crowded, price-sensitive segment that includes polyethylene glycol solutions, sodium picosulfate products and tablet-based preparations.
The market has shifted from branded growth to generic and formulation competition. SUPREP retains value through low-volume dosing and physician familiarity, but long-term revenue growth is constrained by generic entry, payer pressure and newer tablet-based products. Product-specific revenue is not publicly disclosed because the principal commercial owner, Sebela Pharmaceuticals, is privately held.
What is sodium sulfate, potassium sulfate and magnesium sulfate used for?
The combination is an oral osmotic laxative used to cleanse the colon before colonoscopy or other procedures requiring an empty bowel.
SUPREP contains three sulfate salts:
| Component |
Commercial function |
| Sodium sulfate |
Osmotic cathartic |
| Potassium sulfate |
Electrolyte component |
| Magnesium sulfate |
Osmotic cathartic and electrolyte component |
The product is supplied as a concentrated oral solution. Each dose is diluted with water and followed by additional clear liquids. The standard regimen uses two 6-ounce bottles administered in split doses, typically the evening before and the morning of the procedure. The FDA approved SUPREP under NDA 022372 in 2010. [1]
Its principal commercial advantage is lower prep volume than traditional 4-liter polyethylene glycol regimens. Its principal disadvantages are taste, nausea, vomiting, fluid-management requirements and the risk of electrolyte or renal complications in susceptible patients.
How large is the market for sulfate bowel preparations?
The addressable market is the U.S. prescription bowel-preparation market, which is tied to colonoscopy volume rather than to chronic drug utilization.
Key demand drivers include:
- Colorectal cancer screening among adults aged 45 and older.
- Surveillance colonoscopies for patients with prior polyps or cancer.
- Increasing procedure volumes among aging patients.
- Physician preference for split-dose regimens.
- Patient demand for lower-volume preparations.
- Greater adoption of home-based and ambulatory endoscopy.
The Centers for Disease Control and Prevention recommends colorectal cancer screening for most adults aged 45 to 75, creating a broad procedural base for bowel-preparation products. [2] Screening expansion supports volume growth, although the effect is partly offset by insurance restrictions, delayed procedures and competition from lower-cost generic regimens.
Bowel preparation is a recurring procedural pharmaceutical market, but it is not a high-frequency prescription category. Demand depends on the number of colonoscopies performed, and most patients use the product only once per procedure.
How does SUPREP compare with competing bowel-preparation products?
SUPREP competes on volume, tolerability and convenience rather than on clinical superiority established across all patients.
| Product or category |
Active ingredients |
Delivery format |
Competitive position |
| SUPREP |
Sodium sulfate, potassium sulfate, magnesium sulfate |
Low-volume liquid |
Established branded sulfate formulation |
| Generic sulfate solution |
Same active ingredients |
Low-volume liquid |
Price-based substitute |
| GoLYTELY and equivalents |
Polyethylene glycol and electrolytes |
High-volume liquid |
Established, lower-cost option |
| Clenpiq |
Sodium picosulfate, magnesium oxide, citric acid |
Low-volume liquid |
Liquid alternative with different chemistry |
| Plenvu |
Polyethylene glycol, electrolytes and ascorbate |
Lower-volume liquid |
Reduced-volume PEG alternative |
| SUTAB |
Sodium sulfate, magnesium oxide and potassium chloride |
Tablets |
Convenience-driven alternative |
SUTAB is a particularly important competitive product because it uses tablets rather than a sulfate oral solution. Sebela introduced SUTAB after FDA approval in 2020, giving the company a second product positioned around patient convenience and reduced liquid burden. [3]
SUPREP’s differentiation is weaker when payers treat all bowel preparations as therapeutically interchangeable. In that setting, formularies can favor generic sulfate solution or low-cost PEG products.
What is the FDA regulatory status of the product?
SUPREP is an FDA-approved prescription drug marketed under NDA 022372. The FDA labeling identifies the product as an oral solution for colon cleansing before colonoscopy in adults. [1]
The product is not a biologic and has no biosimilar pathway. Competitive entry occurs through abbreviated new drug applications, or ANDAs, for products demonstrating pharmaceutical equivalence and bioequivalence.
The regulatory profile is relatively favorable because:
- The active ingredients are established salts.
- The product has a clear bowel-cleansing endpoint.
- The dosage regimen is standardized.
- The formulation does not require complex device technology.
- Generic manufacturers can rely on established safety and efficacy information through the ANDA pathway.
The main regulatory barriers are formulation consistency, stability, electrolyte specifications, manufacturing controls and labeling requirements concerning renal impairment, dehydration and fluid balance.
What patents protect sodium sulfate, potassium sulfate and magnesium sulfate oral solution?
The historical patent estate centered on the sulfate bowel-preparation formulation and its use in colon cleansing. A principal patent associated with the SUPREP formulation is U.S. Patent No. 6,946,149, assigned to Braintree Laboratories. The patent reached its ordinary 20-year term in 2022 based on its underlying filing timeline. [4]
Core formulation protection
The core patent strategy protected combinations of sulfate salts used to produce bowel cleansing with a reduced volume of solution. The commercial value of this protection depended on whether an ANDA applicant could:
- Wait for expiration;
- File a Paragraph IV certification;
- Design around claimed concentrations or excipients; or
- Challenge claim validity or enforceability.
Method-of-use protection
Method-of-use claims may cover administration of the composition for colon cleansing before a medical procedure. These claims are narrower than broad composition claims because they depend on the claimed dosing method, patient population or procedural use.
Method-of-use protection has less commercial leverage after generic products become available if the generic label carries the same indication or if the use is difficult to distinguish from the approved indication.
Manufacturing and formulation barriers
The most durable practical barriers are not necessarily patent-based. They include:
- Control of sulfate concentration;
- Palatability and flavor masking;
- Stability in concentrated solution;
- Bottle and packaging configuration;
- Batch-to-batch osmolality control;
- Compliance with electrolyte labeling;
- Scale-up reliability.
These factors can delay generic launches but generally do not support premium pricing once several suppliers qualify.
What is the Orange Book status of SUPREP?
SUPREP is listed in the FDA Orange Book under NDA 022372. Orange Book relevance is concentrated in three areas:
- Listed patents and their expiration dates;
- Generic ANDA approvals;
- Paragraph IV certifications and associated litigation.
The commercial significance of the original SUPREP patent estate declined materially after the principal formulation protection reached its term. Current competitive risk is therefore driven more by approved generic products and payer substitution than by a remaining broad blocking patent.
The Orange Book should be treated as the controlling source for current listed-patent status, expiration dates and any later-listed patents. [5]
Which companies are challenging or competing with SUPREP?
Competition comes from both generic manufacturers and branded bowel-preparation companies.
Generic manufacturers
Generic suppliers compete primarily through:
- Wholesale acquisition price;
- Pharmacy and distributor access;
- Formulary contracting;
- Manufacturing reliability;
- Authorized-generic arrangements.
Once multiple ANDAs are approved, price erosion normally accelerates because the product has limited clinical differentiation and low switching costs for pharmacies and payers.
Branded competitors
The major branded competitive groups include:
- Sebela Pharmaceuticals, through SUPREP and SUTAB;
- Ferring Pharmaceuticals, through products such as Clenpiq and Plenvu;
- Generic manufacturers of PEG-electrolyte preparations;
- Companies marketing tablet-based bowel preparations.
The commercial contest has moved toward patient adherence, physician preference, payer coverage and product availability. Clinical claims alone are less likely to sustain a premium without favorable formulary treatment.
What Paragraph IV challenges and litigation affect the product?
SUPREP’s principal patent risk occurred during the period when generic manufacturers sought approval before or near expiration of the formulation patent. ANDA litigation in this category typically involves:
- Paragraph IV allegations that the patent is invalid or not infringed;
- Declaratory judgment actions;
- Settlement agreements permitting an agreed generic launch date;
- Potential authorized-generic supply arrangements.
The core U.S. patent term has now passed, so the financial importance of earlier Paragraph IV disputes is historical unless a later-listed patent remains enforceable. The relevant litigation question is therefore whether any current patent, regulatory exclusivity or contractual arrangement can delay a specific generic product. For the mature sulfate solution, generic entry risk is principally commercial rather than litigation-driven.
Settlement terms in pharmaceutical patent cases are often confidential. Publicly visible launch dates and ANDA approvals may reveal the practical effect of a settlement without disclosing its economic terms.
When does sodium sulfate, potassium sulfate and magnesium sulfate lose exclusivity?
The product lost its principal composition-patent protection when U.S. Patent No. 6,946,149 reached its ordinary term in 2022. FDA approval of generic sulfate oral solutions further reduced effective market exclusivity.
The exclusivity timeline is:
| Event |
Approximate timing |
| FDA approval of SUPREP |
2010 |
| Branded growth and market expansion |
2010-2017 |
| Generic patent challenges and ANDA activity |
Mid-to-late 2010s |
| Generic market entry |
Late 2010s onward |
| Core formulation patent term |
2022 |
| Mature generic and branded competition |
2023 onward |
FDA approval does not itself guarantee commercial exclusivity after patent expiry. Generic manufacturers can enter when patent, regulatory and settlement barriers no longer block approval.
How strong is the patent estate for SUPREP?
The patent estate is now moderate to weak as a basis for long-term exclusivity.
| Factor |
Assessment |
| Core composition patent |
Expired or no longer commercially blocking after 2022 |
| Formulation complexity |
Moderate |
| Generic substitution risk |
High |
| Method-of-use protection |
Narrower and less durable |
| Device dependence |
Low |
| Manufacturing know-how |
Useful but unlikely to block all suppliers |
| Brand recognition |
Meaningful |
| Long-term pricing power |
Limited |
The strongest remaining competitive assets are brand familiarity, physician prescribing habits, distribution, patient experience and payer positioning. Those assets can support share retention, but they do not create the same protection as an enforceable composition patent.
What is the financial trajectory for SUPREP?
Product-specific revenue is not publicly reported by Sebela Pharmaceuticals. The company is privately held, and public financial disclosures do not provide a reliable standalone revenue series for SUPREP.
The financial trajectory can be divided into four phases.
2010-2017: branded expansion
SUPREP benefited from:
- FDA approval of a lower-volume sulfate preparation;
- Growth in colonoscopy screening;
- Physician adoption of split-dose regimens;
- Premium pricing relative to older PEG products;
- Limited early generic competition.
Revenue likely expanded through prescription growth and branded pricing, although audited product-level figures are unavailable.
2018-2022: erosion risk and portfolio defense
Generic ANDA activity placed pressure on the product. The company responded through portfolio management, contracting and expansion into tablet-based preparation with SUTAB.
This period shifted the economic model from reliance on a single liquid product to a broader bowel-preparation portfolio.
2023 onward: mature-market economics
After expiration of the core formulation patent, SUPREP faces:
- Lower net pricing;
- Formulary substitution;
- Generic pharmacy dispensing;
- Greater rebate requirements;
- Reduced return on promotional spending.
The product can remain profitable because bowel preparation has repeat procedural demand, established manufacturing and relatively low development costs. Margin quality is weaker than during the protected branded period.
Medium-term outlook
The likely trajectory is stable-to-declining revenue for the individual SUPREP brand, offset by possible growth in the broader Sebela bowel-preparation portfolio. SUTAB can reduce dependence on the liquid formulation, but it also competes for the same colonoscopy-preparation budget.
What revenue exposure and launch scenarios matter for investors?
The largest exposure is to the U.S. market because the product’s principal commercial and regulatory base is U.S. colonoscopy preparation.
| Scenario |
Market effect |
Financial effect |
| One or two generic suppliers |
Controlled price erosion |
Brand retains some share and contracting leverage |
| Several generic suppliers |
Rapid substitution |
Lower price and lower brand volume |
| Strong SUTAB adoption |
Portfolio offset |
Liquid-product decline partly mitigated |
| Increased colonoscopy screening |
Volume support |
Slows revenue erosion |
| Payer preference for PEG or generic sulfate |
Share loss |
Higher rebate pressure |
| Supply disruption among generics |
Temporary brand recovery |
Short-term volume and pricing benefit |
| New differentiated tablet product |
Share fragmentation |
Greater promotional and contracting costs |
The key earnings variable is net price after rebates rather than prescription count alone. A mature bowel-preparation brand can maintain prescription volume while losing revenue through discounts and formulary concessions.
What generic entry risks exist?
Generic entry risk is high because the product is a small-molecule oral solution with established active ingredients and no biologic manufacturing barrier.
The principal risks are:
- Multiple ANDA approvals;
- Pharmacy substitution;
- Payer mandates;
- Authorized-generic pricing;
- Reduced physician sensitivity to brand;
- Product shortages that shift prescriptions among suppliers;
- New tablet formulations that reduce demand for liquid products.
The main defense is execution: supply reliability, formulary contracts, physician awareness and patient tolerability. Patent litigation is less likely to be the central defense after expiry of the core formulation patent.
What licensing deals affect the market?
The most commercially relevant transactions are portfolio acquisitions and licensing arrangements involving bowel-preparation products rather than the active ingredients themselves. Braintree Laboratories developed SUPREP, and Sebela Pharmaceuticals acquired Braintree’s business in 2016. [6]
Because Sebela is private, transaction-level economics, product-level royalties and SUPREP operating margins are not disclosed in the manner of a public pharmaceutical company.
Licensing value in this market generally depends on:
- Geographic rights;
- Existing FDA approval;
- Manufacturing capacity;
- Formulary access;
- Product differentiation;
- Rights to tablets or lower-volume formulations.
The active pharmaceutical ingredients are generic commodities. Strategic value lies in the finished dosage form, regulatory file, commercial relationships and product portfolio.
Key Takeaways
- Sodium sulfate, potassium sulfate and magnesium sulfate oral solution is primarily the SUPREP bowel-preparation product.
- FDA approval was granted in 2010 under NDA 022372.
- The core formulation patent, U.S. Patent No. 6,946,149, reached its ordinary term in 2022.
- Generic entry has changed the market from protected branded growth to price-sensitive competition.
- SUPREP competes with generic sulfate solutions, PEG products, Clenpiq, Plenvu and SUTAB.
- Biosimilar risk does not apply because this is a small-molecule drug.
- Product-specific revenue is not publicly disclosed because Sebela Pharmaceuticals is privately held.
- The most important commercial defenses are brand recognition, payer access, supply reliability and the broader SUPREP-SUTAB portfolio.
- The likely long-term trajectory is declining standalone SUPREP revenue with continued profitability and possible portfolio-level offset from tablet-based products.
FAQs About Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate
Is sodium sulfate, potassium sulfate and magnesium sulfate the same as SUPREP?
Yes. SUPREP is the principal branded U.S. product containing this three-sulfate combination as an oral bowel-preparation solution.
Is there a generic version of SUPREP?
Yes. FDA-approved generic sulfate oral solutions have entered the U.S. market, creating direct substitution and pricing pressure.
Is SUTAB a generic version of SUPREP?
No. SUTAB is a separate tablet-based bowel preparation with a different formulation, although both products are associated with Sebela and target the same colonoscopy-preparation market.
Does SUPREP have biosimilar competition?
No. Biosimilar regulation applies to biologic products. SUPREP is a small-molecule oral solution and faces generic-drug competition through the ANDA pathway.
Can SUPREP maintain premium pricing after patent expiry?
It can retain a price premium in selected formularies through brand familiarity, physician preference and patient experience, but broad premium pricing is difficult once generic sulfate solutions are available.
References
- U.S. Food and Drug Administration. (2024). SUPREP bowel prep kit: Prescribing information, NDA 022372. https://www.accessdata.fda.gov
- Centers for Disease Control and Prevention. (2024). Screening for colorectal cancer. https://www.cdc.gov/colorectal-cancer/screening
- U.S. Food and Drug Administration. (2020). FDA approves SUTAB tablets for colonoscopy preparation. https://www.fda.gov
- U.S. Patent and Trademark Office. (2005). U.S. Patent No. 6,946,149: Oral purgative compositions. https://patents.google.com
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
- Sebela Pharmaceuticals. (2016). Sebela Pharmaceuticals acquires Braintree Laboratories. Company announcement. https://www.sebelapharma.com
